Inhibikase Therapeutics, Inc. (IKT) Corporate Subsidiaries
Inhibikase Therapeutics, Inc. (IKT) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: IKT
CIK: 1750149
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
CohnReznick LLP
Auditor SinceSince 12/31/2019 12:00:00 AM
Lead Engagement PartnerJesse Stoop
Audit LocationHolmdel, New Jersey, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-09-08 | 2026-09-08 | 8-K | 0001193125-26-385293 | View SEC Doc Filr Page |
| 8-K | 2026-08-26 | 2026-08-21 | 8-K | 0001193125-26-368296 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001193125-26-352638 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001104659-26-097282 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-13 | — | SCHEDULE 13G/A Filing | 0001875620-26-000017 | View SEC Doc Filr Page |
| S-8 | 2026-08-11 | — | S-8 | 0001193125-26-344775 | View SEC Doc Filr Page |
| 10-Q | 2026-08-11 | 2026-06-30 | 10-Q | 0001193125-26-344707 | View SEC Doc Filr Page |
| 8-K | 2026-08-11 | 2026-08-11 | 8-K | 0001193125-26-344623 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-07-31 | — | SCHEDULE 13G/A Filing | 0001346824-26-000206 | View SEC Doc Filr Page |
| 4 | 2026-07-31 | 2026-07-29 | 4 Filing | 0001231919-26-000815 | View SEC Doc Filr Page |
| 4 | 2026-07-31 | 2026-07-30 | 4 | 0001193125-26-328467 | View SEC Doc Filr Page |
| 8-K | 2026-07-29 | 2026-07-29 | 8-K | 0001193125-26-323651 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-07-28 | — | SCHEDULE 13G Filing | 0002012383-26-002526 | View SEC Doc Filr Page |
| 8-K | 2026-07-23 | 2026-07-23 | 8-K | 0001193125-26-313400 | View SEC Doc Filr Page |
| 3 | 2026-07-17 | 2026-07-10 | 3 Filing | 0001231919-26-000769 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-07-17 | — | SCHEDULE 13G Filing | 0001346824-26-000193 | View SEC Doc Filr Page |
| 8-K | 2026-07-14 | 2026-07-14 | 8-K | 0001193125-26-302580 | View SEC Doc Filr Page |
| 4 | 2026-06-30 | 2026-06-26 | 4 | 0001193125-26-290477 | View SEC Doc Filr Page |
| 4 | 2026-06-30 | 2026-06-26 | 4 | 0001193125-26-290476 | View SEC Doc Filr Page |
| 4 | 2026-06-30 | 2026-06-26 | 4 | 0001193125-26-290475 | View SEC Doc Filr Page |
| 4 | 2026-06-30 | 2026-06-26 | 4 | 0001193125-26-290474 | View SEC Doc Filr Page |
| 4 | 2026-06-30 | 2026-06-26 | 4 | 0001193125-26-290472 | View SEC Doc Filr Page |
| 4 | 2026-06-30 | 2026-06-26 | 4 | 0001193125-26-290470 | View SEC Doc Filr Page |
| 8-K | 2026-06-29 | 2026-06-26 | 8-K | 0001193125-26-286747 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-05-15 | — | SCHEDULE 13G/A Filing | 0001104659-26-062874 | View SEC Doc Filr Page |